Real-world use of sorafenib for advanced renal cell carcinoma patients with cardiovascular disease: nationwide survey in Japan-论文-万方医学网

Real-world use of sorafenib for advanced renal cell carcinoma patients with cardiovascular disease: nationwide survey in Japan

导出原文传递

翻译打印收藏纠错

作者： Inamoto, Teruo ^[1] ; Azuma, Haruhito ^[2] ; Tatsugami, Katsunori ^[3] ; Oya, Mototsugu ^[4] ; Adachi, Masatoshi ^[5] ; Okayama, Yutaka ^[6] ; Sunaya, Toshiyuki ^[7] ; Akaza, Hideyuki

作者单位： Osaka Med Coll, Dept Urol, Takatsuki, Osaka, Japan ^[1] Kyushu Univ, Grad Sch Med Sci, Dept Urol, Fukuoka, Japan ^[2] Keio Univ, Dept Urol, Sch Med, Tokyo, Japan ^[3] Bayer Yakuhin Ltd, Med Affairs Oncol & Hematol, Osaka, Japan ^[4] Bayer Yakuhin Ltd, Pharmacovigilance & Med Governance, PMS, Osaka, Japan ^[5] Bayer Yakuhin Ltd, Res & Dev Japan, Stat & Data Insights, Osaka, Japan ^[6] Univ Tokyo, Res Ctr Adv Sci & Technol, Tokyo, Japan ^[7]

关键词 Cardiovascular disease sorafenib prognosis renal cell carcinoma

发布时间 2022-09-10

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除